111TH CONGRESS 

2D SESSION H. R. 5354 

AN ACT 

To provide grants to better understand and reduce 

gestational diabetes, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 5354 EH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Gestational Diabetes 

3 Act of 2010’’ or the ‘‘GEDI Act’’. 

4 SEC. 2. GESTATIONAL DIABETES. 

5 Part B of title III of the Public Health Service Act 

6 (42 U.S.C. 243 et seq.) is amended by adding after section 

7 317H the following: 

8 ‘‘SEC. 317H–1. GESTATIONAL DIABETES. 

9 ‘‘(a) UNDERSTANDING AND MONITORING GESTA10 TIONAL DIABETES.— 

11 ‘‘(1) IN GENERAL.—The Secretary, acting 

12 through the Director of the Centers for Disease 

13 Control and Prevention, in consultation with the Di14 abetes Mellitus Interagency Coordinating Committee 

15 established under section 429 and representatives of 

16 appropriate national health organizations, shall de17 velop a multisite gestational diabetes research 

18 project within the diabetes program of the Centers 

19 for Disease Control and Prevention to expand and 

20 enhance surveillance data and public health research 

21 on gestational diabetes. 

22 ‘‘(2) AREAS TO BE ADDRESSED.—The research 

23 project developed under paragraph (1) shall ad24 dress— 

25 ‘‘(A) procedures to establish accurate and 

26 efficient systems for the collection of gestational 
3 

•HR 5354 EH

1 diabetes data within each State and common2 wealth, territory, or possession of the United 

3 States; 

4 ‘‘(B) the progress of collaborative activities 

5 with the National Vital Statistics System, the 

6 National Center for Health Statistics, and 

7 State health departments with respect to the 

8 standard birth certificate, in order to improve 

9 surveillance of gestational diabetes; 

10 ‘‘(C) postpartum methods of tracking 

11 women with gestational diabetes after delivery 

12 as well as targeted interventions proven to 

13 lower the incidence of type 2 diabetes in that 

14 population; 

15 ‘‘(D) variations in the distribution of diag16 nosed and undiagnosed gestational diabetes, 

17 and of impaired fasting glucose tolerance and 

18 impaired fasting glucose, within and among 

19 groups of women; and 

20 ‘‘(E) factors and culturally sensitive inter21 ventions that influence risks and reduce the in22 cidence of gestational diabetes and related com23 plications during childbirth, including cultural, 

24 behavioral, racial, ethnic, geographic, demo25 graphic, socioeconomic, and genetic factors. 
4 

•HR 5354 EH

1 ‘‘(3) REPORT.—Not later than 2 years after the 

2 date of the enactment of this section, and annually 

3 thereafter, the Secretary shall generate a report on 

4 the findings and recommendations of the research 

5 project including prevalence of gestational diabetes 

6 in the multisite area and disseminate the report to 

7 the appropriate Federal and non-Federal agencies. 

8 ‘‘(b) EXPANSION OF GESTATIONAL DIABETES RE9 SEARCH.— 

10 ‘‘(1) IN GENERAL.—The Secretary shall expand 

11 and intensify public health research regarding gesta12 tional diabetes. Such research may include— 

13 ‘‘(A) developing and testing novel ap14 proaches for improving postpartum diabetes 

15 testing or screening and for preventing type 2 

16 diabetes in women with a history of gestational 

17 diabetes; and 

18 ‘‘(B) conducting public health research to 

19 further understanding of the epidemiologic, 

20 socioenvironmental, behavioral, translation, and 

21 biomedical factors and health systems that in22 fluence the risk of gestational diabetes and the 

23 development of type 2 diabetes in women with 

24 a history of gestational diabetes. 
5 

•HR 5354 EH

1 ‘‘(2) AUTHORIZATION OF APPROPRIATIONS.— 

2 There is authorized to be appropriated to carry out 

3 this subsection $5,000,000 for each fiscal year 2012 

4 through 2016. 

5 ‘‘(c) DEMONSTRATION GRANTS TO LOWER THE RATE

6 OF GESTATIONAL DIABETES.— 

7 ‘‘(1) IN GENERAL.—The Secretary, acting 

8 through the Director of the Centers for Disease 

9 Control and Prevention, shall award grants, on a 

10 competitive basis, to eligible entities for demonstra11 tion projects that implement evidence-based inter12 ventions to reduce the incidence of gestational diabe13 tes, the recurrence of gestational diabetes in subse14 quent pregnancies, and the development of type 2 di15 abetes in women with a history of gestational diabe16 tes. 

17 ‘‘(2) PRIORITY.—In making grants under this 

18 subsection, the Secretary shall give priority to 

19 projects focusing on— 

20 ‘‘(A) helping women who have 1 or more 

21 risk factors for developing gestational diabetes; 

22 ‘‘(B) working with women with a history of 

23 gestational diabetes during a previous preg24 nancy; 
6 

•HR 5354 EH

1 ‘‘(C) providing postpartum care for women 

2 with gestational diabetes; 

3 ‘‘(D) tracking cases where women with a 

4 history of gestational diabetes developed type 2 

5 diabetes; 

6 ‘‘(E) educating mothers with a history of 

7 gestational diabetes about the increased risk of 

8 their child developing diabetes; 

9 ‘‘(F) working to prevent gestational diabe10 tes and prevent or delay the development of 

11 type 2 diabetes in women with a history of ges12 tational diabetes; and 

13 ‘‘(G) achieving outcomes designed to assess 

14 the efficacy and cost-effectiveness of interven15 tions that can inform decisions on long-term 

16 sustainability, including third-party reimburse17 ment. 

18 ‘‘(3) APPLICATION.—An eligible entity desiring 

19 to receive a grant under this subsection shall submit 

20 to the Secretary— 

21 ‘‘(A) an application at such time, in such 

22 manner, and containing such information as the 

23 Secretary may require; and 

24 ‘‘(B) a plan to— 
7 

•HR 5354 EH

1 ‘‘(i) lower the rate of gestational dia2 betes during pregnancy; or 

3 ‘‘(ii) develop methods of tracking 

4 women with a history of gestational diabe5 tes and develop effective interventions to 

6 lower the incidence of the recurrence of 

7 gestational diabetes in subsequent preg8 nancies and the development of type 2 dia9 betes. 

10 ‘‘(4) USES OF FUNDS.—An eligible entity re11 ceiving a grant under this subsection shall use the 

12 grant funds to carry out demonstration projects de13 scribed in paragraph (1), including— 

14 ‘‘(A) expanding community-based health 

15 promotion education, activities, and incentives 

16 focused on the prevention of gestational diabe17 tes and development of type 2 diabetes in 

18 women with a history of gestational diabetes; 

19 ‘‘(B) aiding State- and tribal-based diabe20 tes prevention and control programs to collect, 

21 analyze, disseminate, and report surveillance 

22 data on women with, and at risk for, gesta23 tional diabetes, the recurrence of gestational di24 abetes in subsequent pregnancies, and, for 
8 

•HR 5354 EH

1 women with a history of gestational diabetes, 

2 the development of type 2 diabetes; and 

3 ‘‘(C) training and encouraging health care 

4 providers— 

5 ‘‘(i) to promote risk assessment, high6 quality care, and self-management for ges7 tational diabetes and the recurrence of ges8 tational diabetes in subsequent preg9 nancies; and 

10 ‘‘(ii) to prevent the development of 

11 type 2 diabetes in women with a history of 

12 gestational diabetes, and its complications 

13 in the practice settings of the health care 

14 providers. 

15 ‘‘(5) REPORT.—Not later than 4 years after the 

16 date of the enactment of this section, the Secretary 

17 shall prepare and submit to the Congress a report 

18 concerning the results of the demonstration projects 

19 conducted through the grants awarded under this 

20 subsection. 

21 ‘‘(6) DEFINITION OF ELIGIBLE ENTITY.—In 

22 this subsection, the term ‘eligible entity’ means a 

23 nonprofit organization (such as a nonprofit academic 

24 center or community health center) or a State, trib25 al, or local health agency. 
9 

•HR 5354 EH

1 ‘‘(7) AUTHORIZATION OF APPROPRIATIONS.— 

2 There is authorized to be appropriated to carry out 

3 this subsection $5,000,000 for each fiscal year 2012 

4 through 2016. 

5 ‘‘(d) POSTPARTUM FOLLOW-UP REGARDING GESTA6 TIONAL DIABETES.—The Secretary, acting through the 

7 Director of the Centers for Disease Control and Preven8 tion, shall work with the State- and tribal-based diabetes 

9 prevention and control programs assisted by the Centers 

10 to encourage postpartum follow-up after gestational diabe11 tes, as medically appropriate, for the purpose of reducing 

12 the incidence of gestational diabetes, the recurrence of 

13 gestational diabetes in subsequent pregnancies, the devel14 opment of type 2 diabetes in women with a history of ges15 tational diabetes, and related complications.’’. 

Passed the House of Representatives September 30 

(legislative day September 29), 2010. 

Attest: 

Clerk. 
111TH CONGRESS 

2D SESSION H. R. 5354 

AN ACT 

To provide grants to better understand and reduce 

gestational diabetes, and for other purposes.